This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Imatinib Mesylate in Treating Patients With Gliomas

This study has been completed.
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC Identifier:
First received: June 6, 2002
Last updated: July 23, 2012
Last verified: July 2012

RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and slow the growth of the tumor.

PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have gliomas.

Condition Intervention Phase
Brain and Central Nervous System Tumors Drug: imatinib mesylate Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Open Label Phase II Study On STI571 (Glivec) Administered As A Daily Oral Treatment In Gliomas

Resource links provided by NLM:

Further study details as provided by European Organisation for Research and Treatment of Cancer - EORTC:

Enrollment: 112
Study Start Date: March 2002
Primary Completion Date: August 2004 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the therapeutic activity of imatinib mesylate (in terms of objective response and progression-free survival at 6 months) in patients with gliomas.
  • Determine the safety of this drug in these patients.
  • Determine the pharmacokinetics of this drug in these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to glioma (glioblastoma multiforme vs anaplastic oligodendroglioma or mixed oligoastrocytoma vs anaplastic astrocytoma or recurrent low-grade astrocytoma).

Patients receive oral imatinib mesylate once or twice daily. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 2 months for 6 months and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 77 patients (29 patients with glioblastoma multiforme, 24 patients with anaplastic oligodendroglioma or mixed oligoastrocytoma, and 24 patients with anaplastic astrocytoma or recurrent low-grade astrocytoma) will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed glioblastoma multiforme

    • Recurrent disease by CT scan or MRI
    • No prior chemotherapy OR
    • No more than 1 prior chemotherapy regimen in adjuvant setting or for recurrent disease OR
  • Histologically or cytologically confirmed anaplastic oligodendroglioma, mixed oligoastrocytoma, anaplastic astrocytoma, or recurrent low-grade astrocytoma

    • Failed prior radiotherapy
    • No more than 1 prior chemotherapy regimen

      • Failed adjuvant chemotherapy OR
      • Failed first-line chemotherapy
  • At least 1 bidimensionally measurable target lesion

    • At least 2 cm on contrast-enhanced CT scan or MRI



  • 18 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified


  • Neutrophil count at least 2,000/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • AST and ALT no greater than 2.5 times ULN
  • Alkaline phosphatase no greater than 2.5 times ULN


  • Creatinine less than 1.7 mg/dL


  • Cardiac function normal
  • No ischemic heart disease within the past 6 months
  • Normal 12-lead ECG


  • No other prior or concurrent malignancy except cone-biopsied carcinoma of the cervix or adequately treated basal cell or squamous cell skin cancer
  • No unstable systemic disease
  • No active uncontrolled infection
  • No psychological, familial, sociological, or geographical condition that would preclude study compliance
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months after study


Biologic therapy:

  • No concurrent anticancer biologic agents
  • No concurrent cytokines (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF])


  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosourea)
  • No concurrent chemotherapy

Endocrine therapy:

  • Must be on stable or decreasing dose of corticosteroids for at least 2 weeks


  • See Disease Characteristics
  • At least 3 months since prior brain irradiation
  • No prior high-dose radiotherapy (more than 65 Gy), stereotactic radiosurgery, or internal radiotherapy unless the recurrence is histologically confirmed
  • No concurrent radiotherapy


  • Prior surgery for primary brain tumor within the past 3 months allowed provided one of the following conditions are present:

    • Postoperative imaging within 72 hours after surgery shows a clearly limited target lesion of at least 2 cm
    • Postoperative follow-up shows a progressive and measurable target lesion
    • A second measurable target lesion is present outside the surgical area


  • No concurrent warfarin or other anticoagulants
  • No other concurrent anticancer agents
  • No other concurrent investigational agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00039364

Kaiser Franz Josef Hospital
Vienna, Austria, A-1100
U.Z. Gasthuisberg
Leuven, Belgium, B-3000
Centre de Lutte Contre le Cancer, Georges-Francois Leclerc
Dijon, France, 21079
CRLCC Nantes - Atlantique
Nantes-Saint Herblain, France, 44805
Centre Antoine Lacassagne
Nice, France, 06189
Institut Gustave Roussy
Villejuif, France, F-94805
Azienda Ospedaliera di Padova
Padova, Italy, 35100
Daniel Den Hoed Cancer Center at Erasmus Medical Center
Rotterdam, Netherlands, 3008 AE
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland, CH-1011
United Kingdom
Beatson Oncology Centre
Glasgow, Scotland, United Kingdom, G11 6NT
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Study Chair: Eric Raymond, MD, PhD Gustave Roussy, Cancer Campus, Grand Paris
Study Chair: Martin J. van Den Bent, MD Daniel Den Hoed Cancer Center at Erasmus Medical Center
  More Information

Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC Identifier: NCT00039364     History of Changes
Other Study ID Numbers: EORTC-16011-26013
Study First Received: June 6, 2002
Last Updated: July 23, 2012

Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
recurrent adult brain tumor
adult glioblastoma
adult anaplastic astrocytoma
adult anaplastic oligodendroglioma
adult mixed glioma
adult pilocytic astrocytoma
adult subependymoma
adult giant cell glioblastoma
adult gliosarcoma
adult diffuse astrocytoma

Additional relevant MeSH terms:
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms by Site
Nervous System Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 20, 2017